Verici Dx (VRCI LN)

Analysis

Health Care • United States

Verici Dx is an immuno-diagnostics development company focused on prognostic and diagnostic tests for kidney transplant patients. The company develops a suite of proprietary tests including Clarava, Tuteva, and Protega, utilizing AI-assisted transcriptomic analysis to provide RNA signatures for personalized patient and organ response risk. Verici Dx was founded in 2020 and is headquartered in Cardiff, United Kingdom.

Refresh

Exchange Announcement • 15 Oct 2026 17:39

Holding(s) in Company

Exchange Announcement • 15 Oct 2026 17:33

Holding(s) in Company

Exchange Announcement • 15 Oct 2026 16:12

Holding(s) in Company

Exchange Announcement • 14 Oct 2026 22:21

Holding(s) in Company

Exchange Announcement • 14 Oct 2026 20:20

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00